Abstract:Protein tyrosine phosphatase 1B (PTP1B) is an enzyme that downregulates the insulin receptor. It has been considered as one of the drug targets of diabetes, and the inhibitors for PTP1B to treat type II diabetes have received considerable attention. The study reports a discovery of a new lead compound inhibiting PTP1B. In this work, PTP1B protein was expressed, purified and crystallized to the resolution of 2.1 Angstrom in the condition of 19%similar to 21% PEG8000, 200 mmol/L Mg(Ac)(2)center dot 4H(2)O. Structural based fragment screening was then performed against 768 fragment chemical compounds. These small molecular fragments were soaked with the PTP1B crystals, and three of them were found to bind at the active site A of PTP1B in the crystals. Then 14 kinds of published molecules which bind to the second active site (site B) were chosen. With the structures of these bound fragment compounds, hundreds of moleculars were calculated by computer aided drug design. Compound 20 was selected as the target compound, and it was synthesized by 13 steps with the total yield of 1.7%. The structure of compound 20 was characterized by H-1 NMR and HRMS data. Bioassay of inhibition of PTP1B by the new compounds revealed its IC50 at (3.4 +/- 1.2) mu mol/L, which was better than that of the positive control drug-sodium vanadate. The result of measurement of glucose uptake by insulin resistant HepG2 cells showed that the new compound can improve glucose uptake and had similar effect as Pioglitazone. The acute toxicity of the new compound was tested by using zebrafish larvae at two different concentrations (50 and 500 mu mol/L). The results showed there was no significant difference in heart rate, blood flow and morphology between the experiment and control group of zebrafish. All the results above implied the new compound has a good inhibition on PTP1B and low acute toxicity. It may be a potential lead compound for further drug discovery.

Structure-activity Relationship of Protein Tyrosine Phosphatase 1B Inhibitors

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Recent progress in research on protein tyrosine phosphatase 1B and its inhibitors

Crystal Structure of PTP1B Complexed with a Potent and Selective Bidentate Inhibitor

Recent Advance on PTP1B Inhibitors and Their Biomedical Applications.

Design, Synthesis, Biological Activity and Molecular Dynamics Studies of Specific Protein Tyrosine Phosphatase 1B Inhibitors over SHP-2.

Design, Synthesis of a Novel Phosphatase 1B Inhibitor and the Evaluation of Its Biology Activity and Toxicity in vitro

Functional Significance and Structure-Activity Relationship of Food-Derived Protein Tyrosine Phosphatase 1B Inhibitors

Research Progress on Inhibitors of Protein Tyrosine Phosphatase-1B

Discovery of Bisindole As A Novel Scaffold for Protein Tyrosine Phosphatase 1b Inhibitors

Recent Progress in Protein Tyrosine Phosphatase 1B Inhibitors

Structure-Based Discovery of Small Molecule Inhibitors Targeted to Protein Tyrosine Phosphatase 1B

Protein tyrosine phosphatase 1B (PTP1B) function, structure, and inhibition strategies to develop antidiabetic drugs

Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B.

Toward the Identification of a Reliable 3D-QSAR Model for the Protein Tyrosine Phosphatase 1B Inhibitors

Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors.

Investigation of Selective Binding of Inhibitors to PTP1B and TCPTP by Accelerated Molecular Dynamics Simulations.

The discovery of a novel and selective inhibitor of PTP1B over TCPTP: 3D QSAR pharmacophore modeling, virtual screening, synthesis, and biological evaluation.

Thiazole-based and Thiazolidine-Based Protein Tyrosine Phosphatase 1B Inhibitors As Potential Anti-Diabetes Agents

Molecular Dynamics Studies on the Interactions of Ptp1b with Inhibitors: from the First Phosphate-Binding Site to the Second One

Design and synthesis of imidazolidine-2,4-dione derivatives as selective inhibitors by targeting protein tyrosine phosphatase-1B over T-cell protein tyrosine phosphatase.